Tag Archive for: Phase II study

CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support

/in

CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients CONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech advancing a clinical-stage FXS program Barcelona, Spain – […]

Read more

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

/in

• Phase II study in non-small-cell-lung-cancer (NSCLC) to be run in collaboration with the ETOP IBCSG Partners Foundation across sites in Europe • Study will investigate dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to first-line checkpoint inhibitor therapy Geneva, Switzerland and Amsterdam, The Netherlands, 9 July 2024 – iOnctura, a clinical-stage biopharmaceutical […]

Read more